Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire•09/11/2026•16:04 ET
1
Key Highlights
- ➤EVERLAST-B high-dose group achieved 61% PASI 100 and 86% PASI 90 at Week 16
- ➤EVERLAST-A PASI 100 response reached 71% at Week 28, six months post-dose
- ➤Oruka plans ORKA-001 Phase 3 psoriasis trials in the first half of 2027
- ➤Oruka held $1.2 billion in cash, equivalents, and marketable securities
- ➤Third-quarter net loss widened to $50.0 million from $30.3 million year over year
Expert Statements
Lawrence Klein, Chief Executive Officer of Oruka Therapeutics
“We continued to make rapid progress in the third quarter and shared two new datasets from the EVERLAST program with ORKA-001 that further strengthen our belief that it can set a new standard in psoriatic disease.”
Lawrence Klein, Chief Executive Officer of Oruka Therapeutics
“We look forward to sharing 52-week data from EVERLAST-A later this year and then working to rapidly initiate pivotal studies with this very promising asset.”
Lawrence Klein, Chief Executive Officer of Oruka Therapeutics
“In parallel, we are building depth in our portfolio with ORKA-002 advancing in two Phase 2 studies, and ORKA-004 nearing first-in-human initiation.”
EVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with EVERLAST-A
EVERLAST-A responses continued to deepen to 71% PASI 100 at Week 28, 6 months after last dose
Get started
Create a free account to read the full story.